Research prototype, not medical advice.

02 — Telomere attrition

Primary hallmark ("damage") according to López-Otín et al., Cell 2023 (doi:10.1016/j.cell.2022.11.001).

1. Definition

Progressive shortening and dysfunction of telomeres, the repeated sequences (TTAGGG) that protect the ends of chromosomes. In humans, most somatic cells express little or no telomerase (the enzyme that lengthens them): with each division, telomeres shorten. When they become too short or damaged, the cell perceives them as a DNA break and stops dividing (senescence) or dies (Blackburn 2015, doi:10.1126/science.aab3389; Rossiello 2022, doi:10.1038/s41556-022-00842-x).

In plain terms: telomeres are like the plastic tips of shoelaces. They shorten with each division; when the tip disappears, the lace (the chromosome) frays and the cell stops dividing.

2. Mechanisms and sources

3. Symptoms and clinical manifestations

Telomere syndromes (telomeropathies) — human monogenic evidence: mutations in telomerase genes (TERT, TERC, DKC1, RTEL1…) cause "dyskeratosis congenita" and a spectrum of diseases: bone marrow failure (aplasia), idiopathic pulmonary fibrosis, cirrhosis, early greying, skin and nail abnormalities, increased cancer risk. Adult forms mainly present as pulmonary fibrosis; the age of onset falls from generation to generation (anticipation), because the transmitted telomeres are shorter and shorter (Armanios 2012, doi:10.1038/nrg3246).

Cohorts and meta-analyses:

Key point: short telomeres are an anti-cancer brake. Lengthening them could protect tissues but favour tumours. This is the central trade-off of the hallmark.

Associated diseases: pulmonary fibrosis, bone marrow aplasia, cardiovascular diseases, cirrhosis; cancers (through excess length or through chromosomal instability during a telomere crisis).

4. Interactions with the other hallmarks

Hallmark (2023 numbering)Link with telomere attrition
1. Genomic instabilityDysfunctional telomeres are perceived as breaks; if they fuse, they trigger breakage-fusion-bridge cycles and chromosomal rearrangements.
3. Epigenetic alterationsTelomeres are surrounded by heterochromatin; its loss with age weakens their protection. Subtelomeric regions change their methylation [to verify] (for humans).
4. Loss of proteostasisIndirect link through senescence (secretome, reticulum stress); poorly documented.
6. Deregulated nutrient sensingTelomeric stress interacts with mTOR and sirtuins (through p53 and NAD+); details still debated.
7. Mitochondrial dysfunctionTelomeres → p53 → PGC-1 → mitochondria axis (Sahin 2011).
8. Cellular senescenceMain historical trigger of replicative senescence (Hayflick limit).
9. Stem cell exhaustionBlood, lung and intestinal stem cells are the first affected in telomeropathies (aplasia, fibrosis).
10. Altered intercellular communicationThe secretome of senescent cells of telomeric origin alters neighbouring tissues.
11. Chronic inflammationInflammation and oxidative stress accelerate shortening; telomeric DDR feeds inflammation (vicious circle).
12. DysbiosisLink not established [to verify].

5. Existing or investigational remedies

InterventionTargetLevel of evidenceKey resultSource
Danazol (synthetic androgen)Increases TERT expressionHuman phase 1-2 trial (telomeropathies)In 12 evaluable patients out of 27 enrolled, telomere length gain in 11/12 at 24 months and haematological responses; liver and muscle toxicitiesTownsley 2016, doi:10.1056/NEJMoa1515319
TERT gene therapy (AAV9)Lengthen telomeresPreclinical (mice)Injection in adult (1 year) and old (2 years) mice: +24 % and +13 % median lifespan, better health, no increase in cancersBernardes de Jesus 2012, doi:10.1002/emmm.201200245
Telomerase reactivation (genetic model)Restore telomerasePreclinical (telomerase-deficient mice)Reversal of tissue degeneration (testes, spleen, gut, brain)Jaskelioff 2010, doi:10.1038/nature09603
TA-65 (cycloastragenol, astragalus extract)Presumed telomerase activatorUncontrolled human study, funded by the manufacturerEffects on immune markers; no robust evidence on health or longevityHarley 2011, doi:10.1089/rej.2010.1085
Bone marrow / lung transplantationReplace the failing organClinical practice (telomeropathies)Treats the organ, not the telomere defect; increased toxicity of conditioning regimensArmanios 2012
Lifestyle (stopping smoking, physical activity, stress reduction)Slow attritionObservationalModest associations; causality not provenBlackburn 2015

Finding: no intervention has been shown in humans to improve health by lengthening telomeres outside telomeropathies. Mendelian randomisation suggests an increased cancer risk with longer telomeres (Telomeres MR Collaboration 2017).

6. Open questions

  1. Length or damage? Foci of telomeric DDR in tissues that do not divide (Hewitt 2012; Fumagalli 2012) suggest that mean length measured in blood is not the right indicator.
  2. Value of leukocyte length as a biomarker: high variability between individuals and between methods (qPCR vs Southern blot); weak individual predictive power.
  3. Cancer/degeneration trade-off: can telomerase be activated transiently or in a targeted way without increasing tumour risk? The reassuring mouse results (Bernardes de Jesus 2012) do not translate directly.
  4. Relevance in normal older humans: does telomere shortening contribute to aging outside telomeropathies, or only in certain organs (blood, lung)?
  5. Causality of lifestyle factors: do tobacco, stress and obesity really shorten telomeres, or are these confounders?

7. References

  1. López-Otín C, et al. Hallmarks of aging: an expanding universe. Cell 2023. doi:10.1016/j.cell.2022.11.001
  2. Blackburn EH, Epel ES, Lin J. Human telomere biology: a contributory and interactive factor in aging, disease risks, and protection. Science 2015. doi:10.1126/science.aab3389
  3. Rossiello F, et al. Telomere dysfunction in ageing and age-related diseases. Nat Cell Biol 2022. doi:10.1038/s41556-022-00842-x
  4. Fumagalli M, et al. Telomeric DNA damage is irreparable and causes persistent DNA-damage-response activation. Nat Cell Biol 2012. doi:10.1038/ncb2466
  5. Hewitt G, et al. Telomeres are favoured targets of a persistent DNA damage response in ageing and stress-induced senescence. Nat Commun 2012. doi:10.1038/ncomms1708
  6. Sahin E, et al. Telomere dysfunction induces metabolic and mitochondrial compromise. Nature 2011. doi:10.1038/nature09787
  7. Codd V, et al. Identification of seven loci affecting mean telomere length and their association with disease. Nat Genet 2013. doi:10.1038/ng.2528
  8. Armanios M, Blackburn EH. The telomere syndromes. Nat Rev Genet 2012. doi:10.1038/nrg3246
  9. Haycock PC, et al. Leucocyte telomere length and risk of cardiovascular disease: systematic review and meta-analysis. BMJ 2014. doi:10.1136/bmj.g4227
  10. Telomeres Mendelian Randomization Collaboration. Association between telomere length and risk of cancer and non-neoplastic diseases: a Mendelian randomization study. JAMA Oncol 2017. doi:10.1001/jamaoncol.2016.5945
  11. Townsley DM, et al. Danazol treatment for telomere diseases. NEJM 2016. doi:10.1056/NEJMoa1515319
  12. Bernardes de Jesus B, et al. Telomerase gene therapy in adult and old mice delays aging and increases longevity without increasing cancer. EMBO Mol Med 2012. doi:10.1002/emmm.201200245
  13. Jaskelioff M, et al. Telomerase reactivation reverses tissue degeneration in aged telomerase-deficient mice. Nature 2010. doi:10.1038/nature09603
  14. Harley CB, et al. A natural product telomerase activator as part of a health maintenance program. Rejuvenation Res 2011. doi:10.1089/rej.2010.1085

DOIs verified via the Crossref API on 2026-10-19.